Alnylam Pharmaceuticals, Inc.
$301.11
$3.19(1.07%)
Alnylam Pharmaceuticals, Inc.
ALNY
$301.11
$3.19(1.07%)
Alnylam Pharmaceuticals, Inc.
ALNY
NASDAQ
$301.11
$3.19(1.07%)
Chart
Upcoming Earnings
Next report date
Jul 30, 2026
Report period
Q3 2026
EPS Estimate
$2.01
Revenue Estimate
$1.32B
Key stats
52-Week Range$301.11
$245.96
$495.55
Market capitalization
$40.18BDividend yield (indicated)
0.00%Price to earnings Ratio (TTM)
68.17Basic EPS (TTM)
$2.37Net income (TTM)
$313.75MRevenue (TTM)
$3.71BAvg. volume
1.21MBeta (1Y)
0.38Employees
2.23KMarket capitalization
$40.18BDividend yield (indicated)
0.00%Price to earnings Ratio (TTM)
68.17Basic EPS (TTM)
$2.37Net income (TTM)
$313.75MRevenue (TTM)
$3.71BAvg. volume
1.21MBeta (1Y)
0.38Employees
2.23KScreener Quick Check
Sign in to check this stock against your screeners
Sign InAbout Alnylam Pharmaceuticals, Inc.
Sector
Healthcare
Industry
Biotechnology
CEO
Yvonne L. Greenstreet
Website
www.alnylam.comHeadquarters
675 West Kendall Street, Cambridge, MA, 02142
IPO Date
2004-06-01
Identifiers
ISIN
US02043Q1076Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on...
Related Stocks
$275.66
1D:
-1.3%
1Y:
-17.2%
US1255231003Healthcare
Mkt Cap
$72.68B
P/E Ratio TTM
11.8
Revenue TTM
$274.95B
Beta
0.27
Earnings TTM
$5.96B
Dividend Yield TTM
2.15%
$702.27
1D:
-1.0%
1Y:
16.4%
US75886F1075Healthcare
Mkt Cap
$72.35B
P/E Ratio TTM
16.5
Revenue TTM
$14.34B
Beta
0.40
Earnings TTM
$4.50B
Dividend Yield TTM
0.51%
Dividend Overview
This company does not pay dividends
Financials
Performance
Margin trends
Debt level and coverage
Earnings
Next: Q3 '26
Actual
Estimate
Performance
Margin trends
Debt level and coverage
Earnings
Next: Q3 '26
Actual
Estimate